122 232

Cited 0 times in

Can the Histoculture Drug Response Assay Predict the Clinical Results of Chemotherapy in Breast Cancer?

Other Title
유방암 환자에서 3차원 조직 배양 항암제 감수성 검사의 유용성
Authors
정, 용식; 조, 영업; 서, 영진; 김, 정수; 오, 세정; 임, 철완; 김, 문보; 박, 흥규
Citation
Journal of breast cancer, 10(3):193-198, 2007
Journal Title
Journal of breast cancer
ISSN
1738-67562092-9900
Abstract
Purpose: The behavior of invasive carcinomas in human can be very varied with different individual responses to chemo- therapy. Individualization is crucial to the optimization of che- motherapy. Therefore, the prediction of a tumor? sensitivity to anticancer agents has been the subject of intensive inve- stigation. In order to investigate the pathobiology of breast cancer, it is necessary to maintain or recreate the characte- ristics of the three-dimensional architecture of the tissues in culture. In this study, we have evaluated the relationship bet- ween the Histoculture Drug Response Assay (HDRA) assess- ment and chemotherapy responses in breast cancer patients.



Method: Tumor specimens from 30 patients with breast cancer were evaluated using the HDRA. Tumor tissues were cultured on gelfoam sponge gel in 24-well plates, followed by treatment with a variety of chemotherapeutic agents. All treatments were conducted in triplicate. The sensitivity of a chemotherapy regimen was defined as a tumor inhibition rate (IR) in excess of 30%. Neoadjuvant or palliative chemothe- rapy for patients, using anthracycline or taxane, was conduct- ed on the basis of the established protocols. The responses to treatments were compared with the results of the HDRA.



Results: The mean IR for the combinations of doxorubicin and docetaxel and for FAC and AC were 48, 45, and 36%, respectively. The above partial rate of response to chemo- therapy was 81.1%. The sensitivity and specificity of the HD- RA assessment, with a 30% inhibition rate, were 81.5 and 66.7%, respectively. The positive and negative response prediction values were 91.7 and 44.4%, respectively. The responses to treatments and the results of the HDRA asse- ssment were not correlated with the expressions of the hor- monal receptor or c-erbB2.



Conclusions: In cases in which the inhibition rate is in excess of 30%, the HDRA assessment yielded a high positive res- ponse prediction value. The sensitivity to chemotherapy, as determined by the HDRA, appears to be a good guide for selection in breast cancer patients. Thus the results presented herein should be integrated into future research on the sub- ject.
Keywords
유방암항암화학요법3차원 조직배양 항암제 감수성 검사Cancer stem cellsSelf renewalTargeted therapy
DOI
10.4048/jbc.2007.10.3.193
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
AJOU Authors
정, 용식
Full Text Link
Files in This Item:
193-198.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse